| Year |
Citation |
Score |
| 2024 |
Barnett H, George M, Skanji D, Saint-Hilary G, Jaki T, Mozgunov P. A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical Methods in Medical Research. 9622802231220497. PMID 38263903 DOI: 10.1177/09622802231220497 |
0.317 |
|
| 2023 |
Daniells L, Mozgunov P, Bedding A, Jaki T. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method. Statistics in Medicine. PMID 37614070 DOI: 10.1002/sim.9867 |
0.323 |
|
| 2023 |
Serra A, Mozgunov P, Jaki T. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering. Statistics in Medicine. PMID 37158302 DOI: 10.1002/sim.9752 |
0.302 |
|
| 2023 |
Espinasse A, Solovyeva O, Dimairo M, Weir C, Jaki T, Mander A, Kightley A, Evans J, Lee S, Bedding A, Hopewell S, Rantell K, Liu R, Chan AW, De Bono J, et al. SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol. Bmj Open. 13: e068173. PMID 36990492 DOI: 10.1136/bmjopen-2022-068173 |
0.303 |
|
| 2022 |
Robertson DS, Choodari-Oskooei B, Dimairo M, Flight L, Pallmann P, Jaki T. Point estimation for adaptive trial designs I: A methodological review. Statistics in Medicine. PMID 36451173 DOI: 10.1002/sim.9605 |
0.324 |
|
| 2022 |
Mozgunov P, Jaki T, Gounaris I, Goddemeier T, Victor A, Grinberg M. Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial. Statistics in Medicine. PMID 36428217 DOI: 10.1002/sim.9594 |
0.353 |
|
| 2022 |
Barnett H, Boix O, Kontos D, Jaki T. Dose finding studies for therapies with late-onset toxicities: A comparison study of designs. Statistics in Medicine. PMID 36250912 DOI: 10.1002/sim.9593 |
0.323 |
|
| 2022 |
Zheng H, Grayling MJ, Mozgunov P, Jaki T, Wason JMS. Bayesian sample size determination in basket trials borrowing information between subsets. Biostatistics (Oxford, England). PMID 35993875 DOI: 10.1093/biostatistics/kxac033 |
0.312 |
|
| 2022 |
Wason JMS, Dimairo M, Biggs K, Bowden S, Brown J, Flight L, Hall J, Jaki T, Lowe R, Pallmann P, Pilling MA, Snowdon C, Sydes MR, Villar SS, Weir CJ, et al. Practical guidance for planning resources required to support publicly-funded adaptive clinical trials. Bmc Medicine. 20: 254. PMID 35945610 DOI: 10.1186/s12916-022-02445-7 |
0.308 |
|
| 2022 |
Lee KM, Robertson DS, Jaki T, Emsley R. The benefits of covariate adjustment for adaptive multi-arm designs. Statistical Methods in Medical Research. 9622802221114544. PMID 35876412 DOI: 10.1177/09622802221114544 |
0.332 |
|
| 2022 |
Serra A, Mozgunov P, Jaki T. An order restricted multi-arm multi-stage clinical trial design. Statistics in Medicine. PMID 35048391 DOI: 10.1002/sim.9314 |
0.334 |
|
| 2021 |
Mozgunov P, Cro S, Lingford-Hughes A, Paterson LM, Jaki T. A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial. Pharmaceutical Statistics. PMID 34891221 DOI: 10.1002/pst.2181 |
0.318 |
|
| 2021 |
Ballarini NM, Burnett T, Jaki T, Jennison C, König F, Posch M. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Statistics in Medicine. PMID 33783020 DOI: 10.1002/sim.8949 |
0.313 |
|
| 2021 |
Lee KM, Brown LC, Jaki T, Stallard N, Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials. 22: 203. PMID 33691748 DOI: 10.1186/s13063-021-05150-7 |
0.321 |
|
| 2021 |
Mozgunov P, Knight R, Barnett H, Jaki T. Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study. International Journal of Environmental Research and Public Health. 18. PMID 33466469 DOI: 10.3390/ijerph18010345 |
0.316 |
|
| 2021 |
Mozgunov P, Paoletti X, Jaki T. A benchmark for dose-finding studies with unknown ordering. Biostatistics (Oxford, England). PMID 33409536 DOI: 10.1093/biostatistics/kxaa054 |
0.321 |
|
| 2020 |
Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, ... ... Jaki T, et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research. 12: 483-497. PMID 34191981 DOI: 10.1080/19466315.2020.1790415 |
0.318 |
|
| 2020 |
Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. Bmc Medicine. 18: 352. PMID 33208155 DOI: 10.1186/s12916-020-01808-2 |
0.338 |
|
| 2020 |
Dodd LE, Follmann D, Wang J, Koenig F, Korn LL, Schoergenhofer C, Proschan M, Hunsberger S, Bonnett T, Makowski M, Belhadi D, Wang Y, Cao B, Mentre F, Jaki T. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials (London, England). 1740774520939938. PMID 32674594 DOI: 10.1177/1740774520939938 |
0.378 |
|
| 2020 |
Abbas R, Rossoni C, Jaki T, Paoletti X, Mozgunov P. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation. Clinical Trials (London, England). 1740774520932130. PMID 32631095 DOI: 10.1177/1740774520932130 |
0.395 |
|
| 2020 |
Griffiths G, Fitzgerald R, Jaki T, Corkhill A, Marwood E, Reynolds H, Stanton L, Ewings S, Condie S, Wrixon E, Norton A, Radford M, Yeats S, Robertson J, Darby-Dowman R, et al. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials. 21: 544. PMID 32560744 DOI: 10.1186/S13063-020-04473-1 |
0.336 |
|
| 2020 |
Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, et al. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Bmj (Clinical Research Ed.). 369: m115. PMID 32554564 DOI: 10.1136/Bmj.M115 |
0.37 |
|
| 2020 |
Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, et al. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials. 21: 528. PMID 32546273 DOI: 10.1186/S13063-020-04334-X |
0.374 |
|
| 2020 |
Mozgunov P, Jaki T, Paoletti X. Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies. Biometrical Journal. Biometrische Zeitschrift. PMID 32529689 DOI: 10.1002/Bimj.201900332 |
0.447 |
|
| 2020 |
Mozgunov P, Gasparini M, Jaki T. A surface-free design for phase I dual-agent combination trials. Statistical Methods in Medical Research. 962280220919450. PMID 32338145 DOI: 10.1177/0962280220919450 |
0.425 |
|
| 2020 |
Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, Krause PR, Longini IM, Mulangu S, Muyembe-Tamfum JJ, Nason MC, et al. Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. The New England Journal of Medicine. 382: 1366-1369. PMID 32242365 DOI: 10.1056/Nejmsb1905390 |
0.313 |
|
| 2020 |
Ballarini NM, Chiu YD, König F, Posch M, Jaki T. A critical review of graphics for subgroup analyses in clinical trials. Pharmaceutical Statistics. PMID 32216035 DOI: 10.1002/Pst.2012 |
0.386 |
|
| 2020 |
Whitehead J, Desai Y, Jaki T. Estimation of treatment effects following a sequential trial of multiple treatments. Statistics in Medicine. PMID 32207166 DOI: 10.1002/Sim.8497 |
0.45 |
|
| 2020 |
McWilliam SJ, Rosala-Hallas A, Jones AP, Shaw V, Greenhalf W, Jaki T, Smyth AR, Smyth RL, Pirmohamed M. Author Correction: A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports. 10: 4730. PMID 32152372 DOI: 10.1038/S41598-020-61783-9 |
0.303 |
|
| 2020 |
McWilliam SJ, Rosala-Hallas A, Jones AP, Shaw V, Greenhalf W, Jaki T, Smyth AR, Smyth RL, Pirmohamed M. A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports. 10: 1796. PMID 32020028 DOI: 10.1038/S41598-020-58790-1 |
0.323 |
|
| 2020 |
Wadsworth I, Hampson LV, Jaki T, Sills GJ, Marson AG, Appleton R. A quantitative framework to inform extrapolation decisions in children Journal of the Royal Statistical Society Series a-Statistics in Society. 183: 515-534. DOI: 10.1111/Rssa.12532 |
0.303 |
|
| 2020 |
Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, ... ... Jaki T, et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19 Statistics in Biopharmaceutical Research. 1-15. DOI: 10.1080/19466315.2020.1790415 |
0.36 |
|
| 2019 |
Mozgunov P, Jaki T. Improving safety of the continual reassessment method via a modified allocation rule. Statistics in Medicine. PMID 31859399 DOI: 10.1002/Sim.8450 |
0.438 |
|
| 2019 |
Pallmann P, Wan F, Mander AP, Wheeler GM, Yap C, Clive S, Hampson LV, Jaki T. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical Trials (London, England). 1740774519890146. PMID 31856600 DOI: 10.1177/1740774519890146 |
0.375 |
|
| 2019 |
Graham E, Jaki T, Harbron C. A comparison of stochastic programming methods for portfolio level decision-making. Journal of Biopharmaceutical Statistics. 1-25. PMID 31825729 DOI: 10.1080/10543406.2019.1684307 |
0.347 |
|
| 2019 |
Mozgunov P, Jaki T. A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints. Biometrical Journal. Biometrische Zeitschrift. PMID 31298770 DOI: 10.1002/Bimj.201800313 |
0.434 |
|
| 2019 |
Grayling MJ, Dimairo M, Mander AP, Jaki TF. A review of perspectives on the use of randomization in phase II oncology trials. Journal of the National Cancer Institute. PMID 31218346 DOI: 10.1093/jnci/djz126 |
0.327 |
|
| 2019 |
Kim M, Van Horn ML, Jaki T, Vermunt J, Feaster D, Lichstein KL, Taylor DJ, Riedel BW, Bush AJ. Repeated measures regression mixture models. Behavior Research Methods. PMID 31152385 DOI: 10.3758/S13428-019-01257-7 |
0.334 |
|
| 2019 |
Mozgunov P, Jaki T. An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicity. Journal of the Royal Statistical Society. Series C, Applied Statistics. 68: 347-367. PMID 31007292 DOI: 10.1111/rssc.12293 |
0.344 |
|
| 2019 |
La Gamba F, Jacobs T, Geys H, Jaki T, Serroyen J, Ursino M, Russu A, Faes C. Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned. Pharmaceutical Statistics. PMID 30932327 DOI: 10.1002/Pst.1941 |
0.346 |
|
| 2019 |
Jaki T, Kim M, Lamont A, George M, Chang C, Feaster D, Van Horn ML. The Effects of Sample Size on the Estimation of Regression Mixture Models. Educational and Psychological Measurement. 79: 358-384. PMID 30911197 DOI: 10.1177/0013164418791673 |
0.328 |
|
| 2019 |
Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, Jaki T, Love SB, Odondi L, Weir CJ, Yap C, Bond SJ. How to design a dose-finding study using the continual reassessment method. Bmc Medical Research Methodology. 19: 18. PMID 30658575 DOI: 10.1186/S12874-018-0638-Z |
0.455 |
|
| 2019 |
Bové DS, Yeung WY, Palermo G, Jaki T. Model-Based dose escalation Designs in R with crmPack Journal of Statistical Software. 89: 1-22. DOI: 10.18637/Jss.V089.I10 |
0.434 |
|
| 2018 |
Jaki T, Su TL, Kim M, Lee Van Horn M. An evaluation of the bootstrap for model validation in mixture models. Communications in Statistics: Simulation and Computation. 47: 1028-1038. PMID 30533972 DOI: 10.1080/03610918.2017.1303726 |
0.308 |
|
| 2018 |
Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. Bmc Cardiovascular Disorders. 18: 215. PMID 30482176 DOI: 10.1186/S12872-018-0956-4 |
0.398 |
|
| 2018 |
Dimairo M, Coates E, Pallmann P, Todd S, Julious SA, Jaki T, Wason J, Mander AP, Weir CJ, Koenig F, Walton MK, Biggs K, Nicholl J, Hamasaki T, Proschan MA, et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. Bmc Medicine. 16: 210. PMID 30442137 DOI: 10.1186/S12916-018-1196-2 |
0.364 |
|
| 2018 |
Mozgunov P, Jaki T, Paoletti X. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of Biopharmaceutical Statistics. 1-19. PMID 30352007 DOI: 10.1080/10543406.2018.1535503 |
0.337 |
|
| 2018 |
Ballarini NM, Rosenkranz GK, Jaki T, König F, Posch M. Subgroup identification in clinical trials via the predicted individual treatment effect. Plos One. 13: e0205971. PMID 30335831 DOI: 10.1371/Journal.Pone.0205971 |
0.374 |
|
| 2018 |
Kunz CU, Jaki T, Stallard N. An alternative method to analyse the biomarker-strategy design. Statistics in Medicine. PMID 30260533 DOI: 10.1002/sim.7940 |
0.306 |
|
| 2018 |
Brueckner M, Titman A, Jaki T, Rojek A, Horby P. Performance of different clinical trial designs to evaluate treatments during an epidemic. Plos One. 13: e0203387. PMID 30204799 DOI: 10.1371/journal.pone.0203387 |
0.33 |
|
| 2018 |
Chiu YD, Koenig F, Posch M, Jaki T. Design and estimation in clinical trials with subpopulation selection. Statistics in Medicine. PMID 30088280 DOI: 10.1002/sim.7925 |
0.344 |
|
| 2018 |
Cotterill A, Jaki T. Dose-escalation strategies which use subgroup information. Pharmaceutical Statistics. PMID 29900666 DOI: 10.1002/pst.1860 |
0.345 |
|
| 2018 |
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, ... Jaki T, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. Bmc Medicine. 16: 29. PMID 29490655 DOI: 10.1186/S12916-018-1017-7 |
0.43 |
|
| 2018 |
Abbas R, Rossoni C, Jaki T, Paoletti X, Mozgunov P. A comparison of phase I dose-escalation designs in clinical trials with monotonicity assumption violation Revue D Epidemiologie Et De Sante Publique. 66. DOI: 10.1016/J.Respe.2018.03.336 |
0.417 |
|
| 2017 |
Vradi E, Brannath W, Jaki T, Vonk R. Model selection based on combined penalties for biomarker identification. Journal of Biopharmaceutical Statistics. 1-15. PMID 29072549 DOI: 10.1080/10543406.2017.1378662 |
0.301 |
|
| 2017 |
Barnett HY, Geys H, Jacobs T, Jaki T. Comparing sampling methods for pharmacokinetic studies using model averaged derived parameters. Statistics in Medicine. PMID 28786135 DOI: 10.1002/Sim.7436 |
0.328 |
|
| 2017 |
Yeung WY, Reigner B, Beyer U, Diack C, Sabanés Bové D, Palermo G, Jaki T. Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy. Pharmaceutical Statistics. PMID 28691311 DOI: 10.1002/Pst.1818 |
0.371 |
|
| 2017 |
Williamson SF, Jacko P, Villar SS, Jaki T. A Bayesian adaptive design for clinical trials in rare diseases. Computational Statistics & Data Analysis. 113: 136-153. PMID 28630525 DOI: 10.1016/j.csda.2016.09.006 |
0.355 |
|
| 2017 |
Brückner M, Titman A, Jaki T. Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint. Statistics in Medicine. PMID 28612371 DOI: 10.1002/Sim.7367 |
0.413 |
|
| 2017 |
Hampson LV, Williamson PR, Wilby MJ, Jaki T. A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment. Statistical Methods in Medical Research. 962280217708906. PMID 28589752 DOI: 10.1177/0962280217708906 |
0.443 |
|
| 2016 |
Jaki T, Vasileiou D. Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments. Statistics in Medicine. PMID 27804166 DOI: 10.1002/sim.7159 |
0.328 |
|
| 2016 |
Van Horn ML, Feng Y, Kim M, Lamont A, Feaster D, Jaki T. Using Multilevel Regression Mixture Models to Identify Level-1 Heterogeneity in Level-2 Effects. Structural Equation Modeling : a Multidisciplinary Journal. 23: 259-269. PMID 27274654 DOI: 10.1080/10705511.2015.1035437 |
0.342 |
|
| 2016 |
Lamont A, Lyons MD, Jaki T, Stuart E, Feaster DJ, Tharmaratnam K, Oberski D, Ishwaran H, Wilson DK, Van Horn ML. Identification of predicted individual treatment effects in randomized clinical trials. Statistical Methods in Medical Research. PMID 26988928 DOI: 10.1177/0962280215623981 |
0.34 |
|
| 2016 |
Jaki T, Hampson LV. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection. Statistics in Medicine. 35: 522-33. PMID 26456537 DOI: 10.1002/Sim.6760 |
0.445 |
|
| 2015 |
Van Horn ML, Jaki T, Masyn K, Howe G, Feaster DJ, Lamont AE, George MR, Kim M. Evaluating differential effects using regression interactions and regression mixture models. Educational and Psychological Measurement. 75: 677-714. PMID 26556903 DOI: 10.1177/0013164414554931 |
0.358 |
|
| 2015 |
Pushpakom SP, Taylor C, Kolamunnage-Dona R, Spowart C, Vora J, García-Fiñana M, Kemp GJ, Whitehead J, Jaki T, Khoo S, Williamson P, Pirmohamed M. Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. Bmj Open. 5: e009566. PMID 26474943 DOI: 10.1136/Bmjopen-2015-009566 |
0.341 |
|
| 2015 |
Kim M, Lamont AE, Jaki T, Feaster D, Howe G, Van Horn ML. Impact of an equality constraint on the class-specific residual variances in regression mixtures: A Monte Carlo simulation study. Behavior Research Methods. PMID 26139512 DOI: 10.3758/S13428-015-0618-8 |
0.325 |
|
| 2015 |
Wason JM, Jaki T. A review of statistical designs for improving the efficiency of phase II studies in oncology. Statistical Methods in Medical Research. PMID 26031358 DOI: 10.1177/0962280215588247 |
0.437 |
|
| 2015 |
Davies GR, Phillips PP, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 19: 626-34. PMID 25946350 DOI: 10.5588/Ijtld.14.0988 |
0.412 |
|
| 2015 |
Cotterill A, Lorand D, Wang J, Jaki T. A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data. Statistics in Medicine. 34: 2138-64. PMID 25809576 DOI: 10.1002/Sim.6482 |
0.381 |
|
| 2015 |
Schaarschmidt F, Hofmann M, Jaki T, Grün B, Hothorn LA. Statistical approaches for the determination of cut points in anti-drug antibody bioassays. Journal of Immunological Methods. 418: 84-100. PMID 25733352 DOI: 10.1016/J.Jim.2015.02.004 |
0.345 |
|
| 2015 |
Jaki T. Multi-arm clinical trials with treatment selection: what can be gained and at what price? Clinical Investigation. 5: 393-399. DOI: 10.4155/Cli.15.13 |
0.399 |
|
| 2015 |
Koenig F, Wolfsegger M, Jaki T, Schütz H, Wassmer G. Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation Trials. 16: 218. DOI: 10.1186/1745-6215-16-S2-P218 |
0.436 |
|
| 2015 |
Simpson S, Hampson L, Jaki T, Jones B. Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging Trials. 16: 148. DOI: 10.1186/1745-6215-16-S2-P148 |
0.428 |
|
| 2015 |
Hampson L, Williamson P, Wilby M, Jaki T. Recruitment progression rules for internal pilot studies monitoring recruitment Trials. 16: 1-1. DOI: 10.1186/1745-6215-16-S2-O89 |
0.439 |
|
| 2014 |
Wolfsegger MJ, Gutjahr G, Engl W, Jaki T. A hybrid method to estimate the minimum effective dose for monotone and non-monotone dose-response relationships. Biometrics. 70: 103-9. PMID 24571518 DOI: 10.1111/Biom.12117 |
0.365 |
|
| 2014 |
Jaki T, Lawo JP, Wolfsegger MJ, Allacher P, Horling F. A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. Journal of Pharmaceutical and Biomedical Analysis. 88: 27-35. PMID 24013033 DOI: 10.1016/J.Jpba.2013.08.013 |
0.307 |
|
| 2014 |
Magirr D, Stallard N, Jaki T. Flexible sequential designs for multi-arm clinical trials Statistics in Medicine. 33: 3269-3279. DOI: 10.1002/Sim.6183 |
0.417 |
|
| 2013 |
George MR, Yang N, Jaki T, Feaster DJ, Lamont AE, Wilson DK, Horn ML. Finite Mixtures for Simultaneously Modelling Differential Effects and Non-Normal Distributions. Multivariate Behavioral Research. 48: 816-844. PMID 25717214 DOI: 10.1080/00273171.2013.830065 |
0.352 |
|
| 2013 |
Jaki T, Pallmann P, Wolfsegger MJ. Authors' reply to Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs". Statistics in Medicine. 32: 5487-8. PMID 24302284 DOI: 10.1002/Sim.6000 |
0.4 |
|
| 2013 |
Phillips A, Fletcher C, Atkinson G, Channon E, Douiri A, Jaki T, Maca J, Morgan D, Roger JH, Terrill P. Multiplicity: discussion points from the Statisticians in the Pharmaceutical Industry multiplicity expert group. Pharmaceutical Statistics. 12: 255-9. PMID 23893876 DOI: 10.1002/Pst.1584 |
0.371 |
|
| 2013 |
Jaki T, Pallmann P, Wolfsegger MJ. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs. Statistics in Medicine. 32: 5469-83. PMID 23801551 DOI: 10.1002/Sim.5886 |
0.46 |
|
| 2013 |
George MR, Yang N, Van Horn ML, Smith J, Jaki T, Feaster D, Masyn K, Howe G. Using regression mixture models with non-normal data: Examining an ordered polytomous approach. Journal of Statistical Computation and Simulation. 83: 757-770. PMID 23687397 DOI: 10.1080/00949655.2011.636363 |
0.351 |
|
| 2013 |
Jaki T, Hothorn LA. Statistical evaluation of toxicological assays: Dunnett or Williams test-take both. Archives of Toxicology. 87: 1901-10. PMID 23652543 DOI: 10.1007/S00204-013-1065-X |
0.31 |
|
| 2013 |
Wason JM, Jaki T, Stallard N. Planning multi-arm screening studies within the context of a drug development program. Statistics in Medicine. 32: 3424-35. PMID 23529936 DOI: 10.1002/Sim.5787 |
0.408 |
|
| 2013 |
Jaki T. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clinical Trials (London, England). 10: 344-6. PMID 23378484 DOI: 10.1177/1740774512474375 |
0.378 |
|
| 2013 |
Jaki T, Clive S, Weir CJ. Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemotherapy and Pharmacology. 71: 1107-14. PMID 23299793 DOI: 10.1007/S00280-012-2059-8 |
0.389 |
|
| 2013 |
Jaki T, André V, Su TL, Whitehead J. Designing exploratory cancer trials using change in tumour size as primary endpoint. Statistics in Medicine. 32: 2544-54. PMID 23280944 DOI: 10.1002/Sim.5716 |
0.387 |
|
| 2013 |
Jaki T, Parry A, Winter K, Hastings I. Analysing malaria drug trials on a per-individual or per-clone basis: a comparison of methods. Statistics in Medicine. 32: 3020-38. PMID 23258694 DOI: 10.1002/Sim.5706 |
0.348 |
|
| 2013 |
Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Statistical Methods in Medical Research. PMID 23242385 DOI: 10.1177/0962280212465498 |
0.405 |
|
| 2013 |
Jaki T, Magirr D. Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promisingtreatments Statistics in Medicine. 32: 1150-1163. PMID 23112135 DOI: 10.1002/Sim.5669 |
0.449 |
|
| 2013 |
Jaki T, Magirr D, Stallard N. Treatment selection in multi-arm, multi-stage clinical trials Trials. 14: 1-1. DOI: 10.1186/1745-6215-14-S1-O4 |
0.422 |
|
| 2013 |
Magirr D, Jaki T, Posch M, Klinglmueller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs Biometrika. 100: 985-996. DOI: 10.1093/Biomet/Ast035 |
0.349 |
|
| 2012 |
Wason JM, Jaki T. Optimal design of multi-arm multi-stage trials. Statistics in Medicine. 31: 4269-79. PMID 22826199 DOI: 10.1002/Sim.5513 |
0.436 |
|
| 2012 |
Lee Van Horn M, Smith J, Fagan AA, Jaki T, Feaster DJ, Masyn K, Hawkins JD, Howe G. Not quite normal: Consequences of violating the assumption of normality in regression mixture models. Structural Equation Modeling : a Multidisciplinary Journal. 19: 227-249. PMID 22754273 DOI: 10.1080/10705511.2012.659622 |
0.353 |
|
| 2012 |
Whitehead J, Thygesen H, Jaki T, Davies S, Halford S, Turner H, Cook N, Jodrell D. A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. Statistics in Medicine. 31: 1931-43. PMID 22495759 DOI: 10.1002/Sim.5331 |
0.379 |
|
| 2012 |
Jaki T, Wolfsegger MJ. Non-compartmental estimation of pharmacokinetic parameters for flexible sampling designs. Statistics in Medicine. 31: 1059-73. PMID 21969306 DOI: 10.1002/Sim.4386 |
0.359 |
|
| 2012 |
Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection Biometrika. 99: 494-501. DOI: 10.1093/Biomet/Ass002 |
0.364 |
|
| 2011 |
Jaki T, Lawo JP, Wolfsegger MJ, Singer J, Allacher P, Horling F. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. Journal of Pharmaceutical and Biomedical Analysis. 55: 1148-56. PMID 21561734 DOI: 10.1016/J.Jpba.2011.04.006 |
0.328 |
|
| 2011 |
Wason JM, Jaki T. Optimal design for multi-arm multi-stage clinical trials Trials. 12: 1-1. DOI: 10.1186/1745-6215-12-S1-A4 |
0.433 |
|
| 2011 |
Jaki T, West RW. Symmetric maximum kernel likelihood estimation Journal of Statistical Computation and Simulation. 81: 193-206. DOI: 10.1080/00949650903232664 |
0.304 |
|
| 2011 |
Jaki T, Wolfsegger MJ. Estimation of pharmacokinetic parameters with the R package PK Pharmaceutical Statistics. 10: 284-288. DOI: 10.1002/Pst.449 |
0.339 |
|
| 2010 |
Sperrin M, Jaki T. Direct effects testing: A two-stage procedure to test for effect size and variable importance for correlated binary predictors and a binary response Statistics in Medicine. 29: 2544-2556. PMID 20683850 DOI: 10.1002/Sim.4014 |
0.33 |
|
| 2010 |
Baumgartner B, Jaki T, Wolfsegger MJ, Eder B, Schiviz A, Schwarz HP, Muchitsch EM. Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A Laboratory Animals. 44: 211-217. PMID 20507877 DOI: 10.1258/La.2010.009113 |
0.35 |
|
| 2010 |
Jaki T, Wolfsegger MJ, Lawo JP. Establishing bioequivalence in complete and incomplete data designs using AUCs. Journal of Biopharmaceutical Statistics. 20: 803-20. PMID 20496207 DOI: 10.1080/10543401003618835 |
0.361 |
|
| 2010 |
Jaki T. Bioequivalence and Statistics in Clinical Pharmacology Journal of the Royal Statistical Society Series a-Statistics in Society. 173: 467-468. DOI: 10.1111/J.1467-985X.2009.00634_11.X |
0.304 |
|
| 2009 |
Wolfsegger MJ, Jaki T. Assessing systemic drug exposure in repeated dose toxicity studies in the case of complete and incomplete sampling. Biometrical Journal. Biometrische Zeitschrift. 51: 1017-29. PMID 19998360 DOI: 10.1002/Bimj.200900151 |
0.356 |
|
| 2009 |
Wolfsegger MJ, Jaki T. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs. Journal of Pharmacokinetics and Pharmacodynamics. 36: 479-94. PMID 19847629 DOI: 10.1007/S10928-009-9133-9 |
0.371 |
|
| 2009 |
Wolfsegger MJ, Jaki T, Dietrich B, Kunzler JA, Barker K. A note on statistical analysis of organ weights in non-clinical toxicological studies. Toxicology and Applied Pharmacology. 240: 117-22. PMID 19540255 DOI: 10.1016/J.Taap.2009.06.012 |
0.343 |
|
| 2009 |
Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Statistics in Medicine. 28: 828-47. PMID 19061203 DOI: 10.1002/Sim.3508 |
0.457 |
|
| 2009 |
Jaki T, Wolfsegger MJ, Ploner M. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods. Pharmaceutical Statistics. 8: 12-24. PMID 18407562 DOI: 10.1002/Pst.321 |
0.373 |
|
| 2009 |
Jaki T, Wolfsegger MJ. A Theoretical Framework for Estimation of AUCs in Complete and Incomplete Sampling Designs Statistics in Biopharmaceutical Research. 1: 176-184. DOI: 10.1198/Sbr.2009.0025 |
0.369 |
|
| 2009 |
Jaki T, Webster West R. Maximum kernel likelihood estimation Journal of Computational and Graphical Statistics. 17: 976-993. DOI: 10.1198/106186008X387057 |
0.31 |
|
| 2008 |
Van Horn ML, Fagan AA, Jaki T, Brown EC, Hawkins JD, Arthur MW, Abbott RD, Catalano RF. Using Multilevel Mixtures to Evaluate Intervention Effects in Group Randomized Trials. Multivariate Behavioral Research. 43: 289-326. PMID 26765664 DOI: 10.1080/00273170802034893 |
0.33 |
|
| 2006 |
Wolfsegger MJ, Jaki T. Simultaneous confidence intervals by iteratively adjusted alpha for relative effects in the one-way layout Statistics and Computing. 16: 15-23. DOI: 10.1007/S11222-006-5197-1 |
0.325 |
|
| 2005 |
Wolfsegger MJ, Jaki T. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs. Journal of Pharmacokinetics and Pharmacodynamics. 32: 757-66. PMID 16328101 DOI: 10.1007/S10928-005-0044-0 |
0.36 |
|
| Show low-probability matches. |